Patents by Inventor Jiangjiang Tang

Jiangjiang Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease
    Patent number: 11680062
    Abstract: Disclosed are 3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives, a preparation method and use thereof, and a drug for the treatment of Alzheimer's disease, which relates to the technical field of preparation of acetophenone oxime ether compounds. The (Z)-3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives provided by the present disclosure show a significant effect on the inhibition of NO production, with an EC50 of 2.07-5.41 ?mol/L. Compared with the positive control group of quercetin (with an EC50 of 9.56 ?mol/L) and oxiconazole (with an EC50 of 13.5 ?mol/L), the inhibitory effect is stronger without significant cytotoxicity (cell viability >90%), which can be used to prepare drugs for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: June 20, 2023
    Assignee: NORTHWEST A & F UNIVERSITY
    Inventors: Jiangjiang Tang, Zhaoyuan Bian, Lanfang Huang, Bo Ren, Ping Xiang, Jinming Gao
  • 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20230159503
    Abstract: Disclosed are 3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives, a preparation method and use thereof, and a drug for the treatment of Alzheimer's disease, which relates to the technical field of preparation of acetophenone oxime ether compounds. The (Z)-3,4-methylenedioxyphenylimidazolylethanonexime ether derivatives provided by the present disclosure show a significant effect on the inhibition of NO production, with an EC50 of 2.07-5.41 ?mol/L. Compared with the positive control group of quercetin (with an EC50 of 9.56 ?mol/L) and oxiconazole (with an EC50 of 13.5 ?mol/L), the inhibitory effect is stronger without significant cytotoxicity (cell viability >90%), which can be used to prepare drugs for the treatment of Alzheimer's disease.
    Type: Application
    Filed: February 14, 2022
    Publication date: May 25, 2023
    Inventors: Jiangjiang Tang, Zhaoyuan Bian, Lanfang Huang, Bo Ren, Ping Xiang, Jinming Gao